Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63,053 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li X, Liu Y, Yao H, Wang M, Gao L, Lou J, Mao J, Wu W, Zhou Y, Tang Y, Yan W, Hu Y, Ding C, Chen S, Niu J, Ding Y. Li X, et al. Among authors: wang m. Antimicrob Agents Chemother. 2022 May 17;66(5):e0009422. doi: 10.1128/aac.00094-22. Epub 2022 Apr 11. Antimicrob Agents Chemother. 2022. PMID: 35404074 Free PMC article. Clinical Trial.
First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects.
Zhang H, Gao L, Lou J, Wu M, Chen H, Yang L, Liu J, Zhu X, Li X, Li C, Wang M, Liu C, Guo W, Wang Y, Gao Z, Han L, Wang D, Jin W, Ding Y. Zhang H, et al. Among authors: wang y, wang m, wang d. Front Pharmacol. 2022 May 19;13:873588. doi: 10.3389/fphar.2022.873588. eCollection 2022. Front Pharmacol. 2022. PMID: 35662718 Free PMC article.
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial.
Wu M, Li X, Yang D, Wang M, Zhang H, Li C, Mai J, Yang L, Qi Y, Yu JC, Yang X, Wang Z, Gu C, Ding Y. Wu M, et al. Among authors: wang z, wang m. BioDrugs. 2023 Jan;37(1):89-98. doi: 10.1007/s40259-022-00563-5. Epub 2022 Nov 22. BioDrugs. 2023. PMID: 36417156 Free PMC article. Clinical Trial.
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability.
Zhang H, Fan Y, Gao L, Wang B, Xu T, Wu M, Liu J, Zhu X, Li X, Chen H, Li C, Wang M, Liu C, Mao Y, Yang M, Ding Y. Zhang H, et al. Among authors: wang m, wang b. Expert Opin Investig Drugs. 2022 Nov;31(11):1255-1263. doi: 10.1080/13543784.2022.2151434. Epub 2022 Dec 20. Expert Opin Investig Drugs. 2022. PMID: 36537742 Clinical Trial.
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.
Li X, Liu Y, Wang M, Gao L, Liu J, Zhang H, Wu M, Chen H, Lou J, Wang J, Chen J, Geng G, Ma Z, Ding Y. Li X, et al. Among authors: wang j, wang m. Lancet Infect Dis. 2024 Jun;24(6):650-664. doi: 10.1016/S1473-3099(24)00003-3. Epub 2024 Feb 12. Lancet Infect Dis. 2024. PMID: 38359854 Clinical Trial.
63,053 results
You have reached the last available page of results. Please see the User Guide for more information.